Eli Lilly to buy part of Novartis for $5.4 bn

US pharmaceutical giant Eli Lilly said Tuesday it has reached an agreement to acquire the animal health division of Novartis of Switzerland for $5.4 billion (3.9 billion euros).

In a statement Eli Lilly said the deal will strengthen and diversify its unit, Elanco, and make it the world's second largest in the sector in terms of global revenue.

Under the terms of the agreement, Lilly will acquire all assets of Novartis Animal Health for a total purchase price of approximately $5.4 billion, including anticipated tax benefits, Eli Lilly said.

It plans to fund this acquisition with approximately $3.4 billion of cash-on-hand and $2.0 billion in debt to be issued.

No other financial terms of the transaction were disclosed.

The transaction is expected to close by the end of the first quarter of 2015, subject to regulatory approvals in the US and overseas.

Novartis Animal Health is present in approximately 40 countries and posted 2013 revenue of approximately $1.1 billion.

It is focused on developing better ways to prevent and treat diseases in pets, and farmed fish, the Eli Lilly statement said.

add to favorites email to friend print save as pdf

Related Stories

US jury hits Takeda, Eli Lilly with $9B penalty (Update)

Apr 08, 2014

A U.S. jury ordered Japanese drugmaker Takeda Pharmaceutical Co. and its U.S. counterpart, Eli Lilly and Co., to pay $9 billion in punitive damages over a diabetes medicine linked to cancer. The drug companies said Tuesday ...

Eli Lilly 2013 profit forecast tops expectations

Jan 04, 2013

(AP)—Eli Lilly and Co. said Friday its 2013 earnings will grow more than Wall Street expects, even though the drugmaker will lose U.S. patent protection for two more key products this year.

Recommended for you

Supercomputers link proteins to drug side effects

Oct 20, 2014

New medications created by pharmaceutical companies have helped millions of Americans alleviate pain and suffering from their medical conditions. However, the drug creation process often misses many side ...

No added benefit proven for umeclidinium/vilanterol in COPD

Oct 20, 2014

The drug combination umeclidinium/vilanterol (trade name Anoro) has been approved since May 2014 for adults with chronic obstructive pulmonary disease (COPD). In an early benefit assessment pursuant to the Act on the Reform ...

User comments